Suicidality among Filipino children and adolescents: a cross-sectional study on substance use among Filipino suicidal and parasuicidal child and adolescent patients

Introduction: The year 2000 World Health Organization reports that the age didtribution of suicide has changed such that the rates for those aged 5-44 years old have increased from 40% to 55%, while those aged 45 and above have decreasing suicide rates of 60% to 45%. In the Philippine General Hospital (PGH), the proportion of child and adolescent suicide cases has increased from 35.8% and 26% in 2003-2004 to 41.7% and 58.4% 2005-2006. To date, local studies on risk factors affecting adolescent suicide have not been done and the number of adolescent attempting to kill themselves in a country known for its close family ties and catholic practices continue to rise. Objectives: To describe the profile of Filipino children who committed suicide or parasuicide and characterize them in terms of history of substance use versus patients without a history of substance use in terms of the following variables: demographics, nature of suicide, and risk factors for suicide. Methods: A retrospective cross-sectional chart review of all Filipino charity patients aged 18 years and below, seen at the PGH Department of Emergency Services (DEMS) from the period January 1, 2006 to October 31, 2007 was done. Data was analyzed using frequency count distribution and ratio and proportion. Results and Conclusions: A total of 56 charts were reviewed for the study. The profile of the Filipino child who attempted suicide in this study can be described as: majority is female, single aged 14-18 years, RC, high school students, and unemployed. Most common method of suicide attempt was through ingestion of silver jewelry cleaner following family conflict. No mortality was reported. Suicide risk factors which appear to be significant in this population are substance use, domestic situation, and involvement in a relationship. Further characterization of the group into those with and without a history of substance use also suggests that increasing age, a lower educational attainment, employment status, family history of suicide, marital status of parents, domestic situation, and involvement in a relationship are factors that may influence substance use among this vulnerable population. Recommendations: Early psychiatric evaluation of alcoholic drinkers among adolescents and parental psycho-education in school should be done to curb the rising incidence of suicide attempts in this vulnerable population. Further, prospective and multicenter studies involving more subjects are needed to validate findings in this study.

Olanzapine IM versus haloperidol IM for acute agitation in schizophrenia

Patients with schizophrenia presenting with agitated or violent behavior require pharmacological tranquilization. Olanzapine is the first atypical antipsychotic to have a short acting intramuscular preparation for control of agitation. There is a need to review the efficacy and safety of olanzapine intramuscular compared to intramuscular haloperidol. Objectives: To compare the efficacy of olanzapine intramuscular with haloperidol intramuscular in controlling acute agitation among patients with schizophrenia. Methodology: The authors searched the Cochrane Schizophrenia Group Register (November 2004), Cochrane Database for studies, Cochrane Controlled Trials Register (Issue 1, 2002), MEDLINE (1992 to the present), Clinical Trials.gov, Lilly Trial Registry and ClinicalTrialresults.org. Authors also hand-searched references of journal articles and contacted pharmaceuticals for relevant literature. Articles included in the meta analysis were randomized clinical trials comparing the efficacy of intramuscular olanzapine to intramuscular haloperidol for controlling agitation among patients with schizophrenia. Included studies had participants 18 years old and above who had schizophrenia and were acutely agitated. Intervention included olanzapine intramuscular 10-20 mgs compared with haloperidol 5-10 mgs. Outcomes included were decreased in agitation as measured by time to tranquility, change in PANSS scale or other appropriate scale and mean dose to achieve tranquility. Secondary outcomes measures were occurrence of adverse events, patient and care giver satisfaction and economic costs. Analysis: Two authors independently assessed the quality of the studies. Data were extracted using the Cochrane Data Extraction Form. Missing data from the studies furnished by ClinicalTrialresults.org. Data that were continuous were sing mean change. Difference in mean change was analyzed using inverse variance, fixed effects method at 95% confidence interval. Data that were dichotomous were analyzed using odds or risk ratio using Mantel-Haenszel method at 95% confidence interval. Results: Pooled data from the studies did not show that olanzapine intramuscular was not equal to haloperidol intramuscular in decreasing acute agitation among patients with schizophrenia. In terms of treatment emergent adverse events, the risk for treatment emergent adverse events was more for haloperidol IM compared olanzapine IM. Conclusions: It cannot be said that olanzapine IM and haloperidol IM are not equal in decreasing agitation among patients with schizophrenia. In terms of treatment emergent adverse events, the risk for extrapyramidal side effects and dystonia was more for haloperidal IM compared to olanzapine IM while the risk for abnormal blood pressure was more for olanzapine IM compared to haloperidol IM. There is need to assess other factors like economic cost, patient and caregiver satisfaction which the studies in this meta-analysis did not include.

Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol.

To examine the quality of life (QoL) and clinical outcomes for Asian schizophrenic outpatients treated with olanzapine or haloperidol. Patients were randomized to 24-weeks' treatment with either olanzapine (n = 144) or haloperidol (n = 132) in a double-blind, prospective, multi-country study. The QLS and WHO-BREF were assessed for QoL; the PANSS, BPRS and CGI scales for clinical status; the BAS, AIMS and SAS scales for physical dysfunction. Regardless of antipsychotic, QoL improved significantly at 8 weeks and maintained this improvement at 24 weeks. Compared with haloperidol, olanzapine treatment was associated with significantly better QoL in the WHO-BREF physical and social relationship domains, better improvements in extrapyramidal symptoms in BAS and SAS scores, as well as lower incidence of adverse events. Patients taking haloperidol were more likely to be co-prescribed anticholinergics. The comparatively superior side-effect profile and tolerability of olanzapine may have contributed to enhance domain-specific QoL for these Asian outpatients.